Sector News

Analyst: Valeant better bring back Pearson if it wants to stay in the game

February 29, 2016
Life sciences

Valeant’s board may be weighing whether pneumonia-stricken CEO J. Michael Pearson is ready to return to work. But he’d better return eventually, one analyst says–or the company could find itself in a world of hurt.

The way Nomura’s Shibani Malhotra sees it, the board “may not be comfortable with Pearson returning to the helm.” But if they replace him, the “loss of Pearson as a leader may remove much of the company’s competitive advantage,” she wrote to clients Thursday.

In that scenario, Valeant would “ideally need to replace him with an outsider with extensive pharmaceutical experience,” she believes–a description current interim CEO Howard Schiller, a former CFO at the company, doesn’t match. And if Valeant can’t come up with an outsider pharma vet? “We think the board could choose a more drastic approach and consider selling all or parts of the company,” she wrote.

Thursday, sources told CNBC that Pearson–who went on medical leave Dec. 28–was ready to return to work, but that Valeant’s board was debating whether he should. The report followed Valeant’s announcement from earlier this week that it would restate earnings after an ad hoc committee found $58 million in accounting mistakes related to controversial specialty pharmacy Philidor.

Questions around Pearson’s employment have been swirling since the Philidor drama was in full swing, with a short-seller in October accusing the drugmaker of using the pharmacy to inflate its top line. Those accusations, along with the price-hike uproar that enveloped the drugmaker as Congress demanded justification over increases on Valeant’s heart meds, sent shares–at their all-time high over the summer–into turmoil.

Through it all, though, Valeant has stood by its skipper. “Mike remains focused on running the business,” Valeant told Bloomberg in November. “Valeant’s core business remains strong and is well positioned for growth.”

By Carly Helfand

Source: Fierce Pharma

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend